Sarah Kim

Sarah Kim, Ph.D.

Assistant Professor

Department: Pharmaceutics
Business Phone: (407) 313-7044
Business Email: sarahkim@ufl.edu

About Sarah Kim

Sarah Kim, Ph.D., is a practicing pharmacometrician with a background in Applied Mathematics and a tenure-track Assistant Professor in the Department of Pharmaceutics at the University of Florida (UF) College of Pharmacy. She graduated summa cum laude from Hanyang University with a B.S. and M.S. in Applied Mathematics. She received her Ph.D. degree in Mathematics from Florida State University. During her postdoctoral training at UF Center for Pharmacometrics and Systems Pharmacology, she received recognition from the international pharmacometrics scientific community, including the David Goldstein Award and multiple Presidential Trainee Awards from the American Society for Clinical Pharmacology and Therapeutics (ASCPT).

Dr. Kim is currently leading several computational modeling projects to create and innovate quantitative solutions in healthcare, with the theme of Model-informed and AI-powered Drug Development. Since 2019, she has secured research funding as the PI, including the NIH National Center for Advancing Translational Sciences R21 award, two JDRF-funded projects, Sail Bio, Critical Path Institute, and four pharmaceutical industry research agreement funds. In addition, she is a co-investigator of the NIH National Institute of Allergy and Infectious Diseases R01 award. Through these research projects, her trainees have received multiple awards.

Dr. Kim is a course coordinator and one of the core instructors of the Population Pharmacokinetics and Pharmacodynamics course. She has been serving as an AI initiative committee member at the UF College of Pharmacy since 2020, as a Pharmacometrics & Pharmacokinetics Community Steering Committee member of ASCPT since 2022, and as an Editorial Advisory Board member for the Journal of Pharmacokinetics and Pharmacodynamics since 2023.

Related Links:

Accomplishments

Peer Review Award for Pharmacology & Toxicology
2018 · Publons
Presidential Trainee Award
2018 · American Society for Clinical Pharmacology and Therapeutics
David Goldstein Trainee Award
2017 · American Society for Clinical Pharmacology and Therapeutics
Presidential Trainee Award
2017 · American Society for Clinical Pharmacology and Therapeutics
Landahl Travel Grant
2015 · Society of Mathematical Biology
Scholarship
2012-2013 · Southern Scholarship Foundation
Pi Mu Epsilon Honor
2012 · National Pi Mu Epsilon Council
Poster Presentation Award
2009 · Korean Society for Mathematical Biology
Graduate Research Fellowship
2008-2010 · LG Corporation Yonam Foundation
Summa Cum Laude Graduation Honors
2008 · Hanyang University
Volunteer Corps Essay Contest Award
2007 · Hanyang University
Full Tuition Scholarship
2004-2007 · Hanyang University

Teaching Profile

Courses Taught
2021-2023
PHA6125 Introduction to Quantitative Pharmacology
2022-2024
PHA6910 Supervised Research
2023-2025
PHA6935 Selected Topics in Pharmacy
2023-2025
PHA7979 Advanced Research
2024-2025
PHA6122 Population Pharmacokinetics and Pharmacodynamics

Research Profile

Dr. Sarah Kim has developed two pillars of the research focus with a model-informed and AI-powered drug development theme: 1. disease-drug-trial modeling and simulation and 2. AI applications to maximize the use of imaging data in drug development.

1. Disease-drug-trial modeling and simulation: We are developing disease progression model-based clinical trial simulation tools to optimize clinical trial designs to investigate potential therapies’ efficacy for Duchenne Muscular Dystrophy, Type 1 Diabetes, and Autosomal Dominant Tubulointerstitial Kidney Disease. In addition, we are developing population pharmacokinetic/ pharmacodynamic (PK/PD) models to inform experimental designs of anti-Mycobacterium Tuberculosis agents to identify optimal regimens which markedly shorten the length of Tuberculosis treatments and prevent the emergence of resistance.

2. AI applications to maximize the use of imaging data in drug development: We are developing AI-assisted imaging analysis and informatics tools that will accelerate feature extraction from imaging data and provide insights into a better understanding of disease progression for Type 1 Diabetes and Duchenne Muscular Dystrophy.

Open Researcher and Contributor ID (ORCID)

0000-0002-9179-0735

Publications

2024
Clinical importance of changes in magnetic resonance biomarkers for Duchenne muscular dystrophy
Annals of Clinical and Translational Neurology. 11(1):67-78 [DOI] 10.1002/acn3.51933. [PMID] 37932907.
2024
Five multivariate Duchenne muscular dystrophy progression models bridging six-minute walk distance and MRI relaxometry of leg muscles
Journal of Pharmacokinetics and Pharmacodynamics. [DOI] 10.1007/s10928-024-09910-1.
2024
Pharmacokinetic and Pharmacodynamic Analysis of Acetaminophen and Ibuprofen Dual Therapy for Patent Ductus Arteriosus Closure in Preterm Neonates at Less Than 29 Weeks of Gestation
The Journal of Clinical Pharmacology. 64(3):312-322 [DOI] 10.1002/jcph.2386.
2024
Type 1 diabetes prevention clinical trial simulator: Case reports of model‐informed drug development tool
CPT: Pharmacometrics & Systems Pharmacology. [DOI] 10.1002/psp4.13193.
2023
Disease progression joint model predicts time to type 1 diabetes onset: Optimizing future type 1 diabetes prevention studies
CPT: Pharmacometrics & Systems Pharmacology. 12(7):1016-1028 [DOI] 10.1002/psp4.12973. [PMID] 37186151.
2023
Future Opportunities in Drug Development: American Society for Clinical Pharmacology and Therapeutics Pharmacometrics and Pharmacokinetics Community Vision
Clinical Pharmacology & Therapeutics. 114(3):507-510 [DOI] 10.1002/cpt.2955.
2023
Multivariate modeling of magnetic resonance biomarkers and clinical outcome measures for Duchenne muscular dystrophy clinical trials
CPT: Pharmacometrics & Systems Pharmacology. 12(10):1437-1449 [DOI] 10.1002/psp4.13021. [PMID] 37534782.
2023
Requirements, expectations, challenges and opportunities associated with training the next generation of pharmacometricians
CPT: Pharmacometrics & Systems Pharmacology. 12(7):883-888 [DOI] 10.1002/psp4.12970. [PMID] 37452453.
2023
Rewiring Drug Research and Development through Human Data-Driven Discovery (HD3)
Pharmaceutics. 15(6) [DOI] 10.3390/pharmaceutics15061673. [PMID] 37376121.
2022
A case study of a patient-centered reverse translational systems-based approach to understand adverse event profiles in drug development.
Clinical and translational science. [DOI] 10.1111/cts.13219. [PMID] 35014203.
2022
A Randomized, Cross‐over Trial of Metoprolol Succinate Formulations to Evaluate PK and PD Endpoints for Therapeutic Equivalence
Clinical and Translational Science. [DOI] 10.1111/cts.13294.
2022
Advancing drug safety science by integrating molecular knowledge with post-marketing adverse event reports.
CPT: pharmacometrics & systems pharmacology. [DOI] 10.1002/psp4.12765. [PMID] 35143713.
2022
Application of a patient-centered reverse translational systems-based approach to understand mechanisms of an adverse drug reaction of immune checkpoint inhibitors.
Clinical and translational science. [DOI] 10.1111/cts.13254. [PMID] 35191192.
2022
Combination Therapy to Kill Mycobacterium tuberculosis in Its Nonreplicating Persister Phenotype
Antimicrobial Agents and Chemotherapy. 66(10) [DOI] 10.1128/aac.00695-22. [PMID] 36165631.
2022
Evaluating Genetic Modifiers of Duchenne Muscular Dystrophy Disease Progression Using Modeling and MRI
Neurology. 99(21) [DOI] 10.1212/wnl.0000000000201163.
2022
Evaluating the effect of clofazimine against Mycobacterium tuberculosis given alone or in combination with pretomanid, bedaquiline or linezolid.
International journal of antimicrobial agents. 59(2) [DOI] 10.1016/j.ijantimicag.2021.106509.
2021
Building optimal 3-drug combination chemotherapy regimens to eradicate Mycobacterium tuberculosis in its slow growth acid phase.
Antimicrobial agents and chemotherapy. [DOI] 10.1128/AAC.00693-21.
2021
Development of a Model-based Clinical Trial Simulation Platform to Optimize the Design of Clinical Trials for Duchenne Muscular Dystrophy.
CPT: pharmacometrics & systems pharmacology. [DOI] 10.1002/psp4.12753. [PMID] 34877803.
2021
Dose Fractionation of Moxifloxacin for Treatment of Tuberculosis: Impact of Dosing Interval and Elimination Half-Life on Microbial Kill and Resistance Suppression
Antimicrobial Agents and Chemotherapy. 65(4) [DOI] 10.1128/aac.02533-20.
2021
In Vitro Synergistic Interactions of Isavuconazole and Echinocandins against Candida auris.
Antibiotics (Basel, Switzerland). 10(4) [DOI] 10.3390/antibiotics10040355. [PMID] 33800601.
2021
Physiologically Based Pharmacokinetics Modeling to Investigate Formulation Factors Influencing the Generic Substitution of Dabigatran Etexilate.
CPT: pharmacometrics & systems pharmacology. [DOI] 10.1002/psp4.12589. [PMID] 33449439.
2021
The Funnel: a Screening Technique for Identifying Optimal Two-Drug Combination Chemotherapy Regimens
Antimicrobial Agents and Chemotherapy. 65(2) [DOI] 10.1128/aac.02172-20.
2020
Assessing the impact of cystic fibrosis on the antipyretic response of ibuprofen in children: Physiologically-based modeling as a candle in the dark.
British journal of clinical pharmacology. 86(11):2247-2255 [DOI] 10.1111/bcp.14326. [PMID] 32335930.
2020
Building Optimal Three-Drug Combination Chemotherapy Regimens
Antimicrobial Agents and Chemotherapy. 64(11) [DOI] 10.1128/aac.01610-20.
2020
Developing New Drugs for Mycobacterium tuberculosis Therapy: What Information Do We Get from Preclinical Animal Models?
Antimicrobial Agents and Chemotherapy. 64(12) [DOI] 10.1128/aac.01376-20.
2020
Examination of Metoprolol Pharmacokinetics and Pharmacodynamics Across CYP2D6 Genotype-Derived Activity Scores.
CPT: pharmacometrics & systems pharmacology. 9(12):678-685 [DOI] 10.1002/psp4.12563. [PMID] 33067866.
2020
Machine Learning in Drug Discovery and Development Part 1: A Primer
CPT: Pharmacometrics & Systems Pharmacology. 9(3):129-142 [DOI] 10.1002/psp4.12491. [PMID] 31905263.
2020
Open Data Revolution in Clinical Research: Opportunities and Challenges.
Clinical and translational science. 13(4):665-674 [DOI] 10.1111/cts.12756. [PMID] 32004409.
2020
Pharmacokinetics of tedizolid, sutezolid, and sutezolid-M1 in non-human primates
European Journal of Pharmaceutical Sciences. 151 [DOI] 10.1016/j.ejps.2020.105421.
2020
Predicting Cost‐Effectiveness of Generic vs. Brand Dabigatran Using Pharmacometric Estimates Among Patients with Atrial Fibrillation in the United States
Clinical and Translational Science. 13(2):352-361 [DOI] 10.1111/cts.12719. [PMID] 32053288.
2020
Quantitative Benefit-Risk Assessment of P-gp-Mediated Drug-Drug Interactions of Dabigatran Coadministered With Pharmacokinetic Enhancers in Patients With Renal Impairment.
Clinical pharmacology and therapeutics. [DOI] 10.1002/cpt.2087. [PMID] 33073366.
2020
Using Physiologically Based Pharmacokinetic Modeling to Assess the Risks of Failing Bioequivalence Criteria: a Tale of Two Ibuprofen Products.
The AAPS journal. 22(5) [DOI] 10.1208/s12248-020-00495-4. [PMID] 32830289.
2019
Evaluating the Clinical Impact of Formulation Variability: A Metoprolol Extended-Release Case Study.
Journal of clinical pharmacology. 59(9):1266-1274 [DOI] 10.1002/jcph.1433. [PMID] 31087554.
2019
Pharmacometrics, Physiologically Based Pharmacokinetics, Quantitative Systems Pharmacology-What’s Next?-Joining Mechanistic and Epidemiological Approaches.
CPT: pharmacometrics & systems pharmacology. 8(6):352-355 [DOI] 10.1002/psp4.12425. [PMID] 31179639.
2019
Towards regulatory endorsement of drug development tools to promote the application of model-informed drug development in Duchenne muscular dystrophy.
Journal of pharmacokinetics and pharmacodynamics. 46(5):441-455 [DOI] 10.1007/s10928-019-09642-7. [PMID] 31127458.
2017
Alterations in Pharmacokinetics of Gemcitabine and Erlotinib by Concurrent Administration of Hyangsayukgunja-Tang, a Gastroprotective Herbal Medicine
Molecules. 22(9) [DOI] 10.3390/molecules22091515. [PMID] 28891960.
2015
A Biomechanical Model of Cortical Folding
Association for Women in Mathematics Series. 41-55 [DOI] 10.1007/978-3-319-16348-2_4.

Grants

Jan 2023 ACTIVE
Optimizing Multi-drug Mycobacterium tuberculosis Therapy for Rapid Sterilization and Resistance Suppression
Role: Co-Investigator
Funding: NATL INST OF HLTH NIAID
Aug 2022 ACTIVE
Quantifying Clinical and Genetic Factors Influencing Rate and Severity of Mucin1 (MUC1) and Uromodulin (UMOD) Variants of Autosomal Dominant Tubulointerstitial Kidney Disease
Role: Principal Investigator
Funding: SAIL BIO
Jun 2022 ACTIVE
Deep Learning-based Analyses of Pancreatic Islet Beta-Cell Heterogeneity and MRI Pancreas Volume as Biomarkers to Improve Understanding of Type 1 Diabetes Progression
Role: Principal Investigator
Funding: BREAKTHROUGH T1D – formerly JDRF Intl
Sep 2021 ACTIVE
Optimizing Muscular Dystrophy Clinical Trial Designs using Modeling and Simulation
Role: Principal Investigator
Funding: NATL INST OF HLTH NCATS
Feb 2020 – Jan 2023
A Model-based Clinical Trial Simulation Tool to Optimize Clinical Trial Designs for Type 1 Diabetes Prevention Studies
Role: Principal Investigator
Funding: BREAKTHROUGH T1D – formerly JDRF Intl
Jul 2019 – Jun 2024
OoR Matching Support for CTSI
Role: Project Manager
Funding: UF DIV OF SPONSORED RES MATCHING FUNDS
Mar 2019 – Mar 2020
A Model-based Clinical Trial Simulation Tool to Optimize Clinical Trial Design of Studies to Investigate Efficacy of Potential Therapies for Duchenne Muscular Dystrophy
Role: Principal Investigator
Funding: CRITICAL PATH INSTITUTE

Education

Ph.D.
2015 · Florida State University
M.S.
2010 · Hanyang University
B.S.
2008 · Hanyang University

Contact Details

Phones:
Business:
(407) 313-7044
Emails:
Business:
sarahkim@ufl.edu
Addresses:
Business Mailing:
6550 SANGER RD
ORLANDO FL 32827
Business Street:
6550 SANGER RD OFC 471
ORLANDO FL 32827